PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26221N0039Eliglustat medication period of performance: 10 — Genzyme Corp

Public-record facts for this award are shown above. Open SCOUT for live scoring relative to your firm, watchlists, and capture workflow.

262-Network Contract Office 22l (36C262)

Awarding office

Genzyme Corp

Recipient

—

Estimated value

6505

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Federal

Contract number36C26221N0039

Also listed as36C262-21-N-0039

Agency262-Network Contract Office 22l (36C262)

Awarding office262-Network Contract Office 22l (36C262)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentGenzyme Corp

UEIX2XMAQLR9DA8

PSC6505

Eliglustat Medication Period of Performance: 10/1/2020 to 9/30/2021 is a federal award for 262-Network Contract Office 22l (36C262) held by Genzyme Corp. Estimated value —.

Eliglustat medication period of performance: 10/1/2020 to 9/30/2021. Latest action is a modification.

Want the durability read on 36C26221N0039? One Pursuit Analysis, $500, inside 48 business hours.

48 business hours
$500
Credits toward the Pack

Buy one Pursuit Analysis — $500

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26221N0039?

36C26221N0039 (Eliglustat medication period of performance: 10) is a 262-Network Contract Office 22l (36C262) award with an estimated value of —, currently held by Genzyme Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C262-21-N-0039?

36C262-21-N-0039 is the dashed form of PIID 36C26221N0039 (Eliglustat medication period of performance: 10), held by Genzyme Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26221N0039?

262-Network Contract Office 22l (36C262) awarded 36C26221N0039 to Genzyme Corp.

Who is the incumbent on 36C26221N0039?

Genzyme Corp is the incumbent.

When does Genzyme Corp’s 36C26221N0039 come up for recompete?

SCOUT tracks a period-of-performance end of an unstated date. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 36C26221N0039? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.